FDA Cites Facilities in China, Japan, and India Post author:Sam Post published:February 14, 2017 Post category:Drug Industry Daily The FDA issued warning letters to four overseas manufacturers over GMP and other failures. Source: Drug Industry Daily You Might Also Like USPTO to Decide on Patent Extension for AAV Tech Used in Novartis’ Zolgensma March 21, 2022 Approvals for 505(b)(2) Drugs Slower Than for NMEs, Report Says March 10, 2017 Westminster Recalls Two Thyroid Drugs Due to API Supplier’s Deficiencies August 16, 2018